Table 4 miRNA characteristics in clinical trials
From: microRNAs as therapeutic targets in intestinal diseases
Company | Drug name | miRNA | Disease | Trials | Reference |
|---|---|---|---|---|---|
Santaris Pharma A/S and Hoffmann-La Roche | Mirvirasen | miR-122 inhibitor | Hepatitis C | Phase II | [114] |
Regulus Therapeutics | RG-101 | miR-122 inhibitor | Chronic hepatitis C | Phase II | / |
miRagen Therapeutics | MRG-106 | miR-155 inhibitor | Cutaneous T cell lymphoma | Phase I | / |
miRagen Therapeutics | MRG-201 | miR-29 mimic | Scleroderma | Phase I | / |
Mirna Therapeutics | MRX34 | miR-34 mimic | Multiple solid tumours | Phase I | |
EnGeneIC | MesomiR-1 | miR-16 mimic | Mesothelioma, non-small cell lung cancer | Phase I | [120] |
Regulus Therapeutics | RG-125 | miR-103/107 inhibitor | Type 2 diabetes and non-alcoholic fatty liver | Phase I | [121] |
Regulus Therapeutics | RG-012 | miR-21 inhibitor | Alport syndrome | Phase I | [122] |